Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.
Profitability
This table compares Aardvark Therapeutics and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aardvark Therapeutics | N/A | -61.71% | -56.29% |
| Contineum Therapeutics | N/A | -27.09% | -25.64% |
Earnings & Valuation
This table compares Aardvark Therapeutics and Contineum Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aardvark Therapeutics | N/A | N/A | -$57.59 million | ($3.21) | -1.20 |
| Contineum Therapeutics | $50.00 million | 9.51 | -$59.98 million | ($1.95) | -6.52 |
Aardvark Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for Aardvark Therapeutics and Contineum Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aardvark Therapeutics | 2 | 4 | 6 | 1 | 2.46 |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 413.02%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 57.23%. Given Aardvark Therapeutics’ higher probable upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Contineum Therapeutics.
Risk and Volatility
Aardvark Therapeutics has a beta of 4.5, suggesting that its stock price is 350% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Summary
Aardvark Therapeutics beats Contineum Therapeutics on 6 of the 11 factors compared between the two stocks.
About Aardvark Therapeutics
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
